US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 2.1600
- +0.0100+0.47%
Close Nov 1 16:00 ET
- 2.1600
- 0.00000.00%
Post 20:02 ET
13.17MMarket Cap-831P/E (TTM)
2.2461High2.0400Low31.61KVolume2.2000Open2.1500Pre Close67.89KTurnover0.52%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High5.31P/B13.17MFloat Cap1.830052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM9.59%Amplitude1.5200Historical Low2.1470Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Can-Fite BioPharma Stock Forum
7 MINUTES AGO, 9:06 AM EDT
VIA GLOBENEWSWIRE
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the Company’s oncology drug candidate, Namodenoson, has been granted O...
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...
Rhe FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
No comment yet